← Blog · Pregnancy Tracking · · 9 min read
The Nuchal Translucency Scan and Genetic Tests: What Every Parent Should Understand
A clear, simple guide to the NT scan, combined screening, NIPT, CVS, and amniocentesis — what they test, what the results mean, and what comes next.
Between 11 and 14 weeks of pregnancy, most healthcare systems offer a scan that looks at something most parents have never heard of: a small pocket of fluid at the back of the baby's neck. The test is called the nuchal translucency (NT) scan, and together with a set of optional blood tests, it forms the first real checkpoint for assessing the baby's risk of certain chromosomal conditions. This article explains what the scan measures, what the numbers mean, and how it fits into the wider landscape of genetic testing in pregnancy.
What the NT scan actually measures
During the first trimester, all developing babies have a thin layer of fluid beneath the skin at the back of the neck. The sonographer measures the thickness of this fluid — the nuchal translucency — on an ultrasound taken when the baby is between 11 weeks and 13 weeks 6 days. The measurement must be taken in a very precise position: the baby must be lying on their back, with the head in a neutral angle, and the image must be magnified so that the amniotic membrane is clearly separate from the fetal skin.
The thickness of this fluid is what matters. In most pregnancies, it is very small — usually under 2.5 or 3.0 millimetres, depending on the exact gestational age. A larger measurement does not mean something is wrong. It means the background risk of certain chromosomal conditions is higher, and further testing may be offered.
What conditions the NT scan screens for
The NT scan is a screening test, not a diagnosis. It estimates risk. It does not tell you whether the baby has a condition. The main conditions it screens for are:
- Down syndrome (Trisomy 21) — an extra copy of chromosome 21. The most common chromosomal condition, associated with characteristic physical features and varying degrees of intellectual disability. Most children with Down syndrome live full, healthy lives into adulthood.
- Edwards syndrome (Trisomy 18) — an extra copy of chromosome 18. Much more severe than Trisomy 21. Most babies with Edwards syndrome do not survive to birth; those who do usually have profound physical and developmental challenges.
- Patau syndrome (Trisomy 13) — an extra copy of chromosome 13. Also very severe. Survival beyond the first year is rare, and affected babies typically have multiple serious organ defects.
A larger-than-expected NT measurement can also signal structural heart defects, other chromosomal differences, or rare genetic syndromes — even when the common trisomies are not present. It can also, in some cases, mean nothing at all.
The combined test: NT plus blood
The NT scan on its own is only moderately accurate. Most healthcare systems combine it with a first-trimester blood test to improve precision. The combined test is usually called the combined screening test or first-trimester screening.
The blood test measures two substances:
- PAPP-A (Pregnancy-Associated Plasma Protein-A) — a protein produced by the placenta. Low levels are associated with higher risk of chromosomal conditions.
- Free beta-hCG (human chorionic gonadotropin) — a hormone also produced by the placenta. Abnormally high or low levels shift the risk calculation.
The laboratory combines the NT measurement, the blood results, the mother's age, weight, ethnicity, and gestational age into a single risk figure. You receive a result like "1 in 1,000" or "1 in 50." This is not a probability you can simply convert into a percentage. It means that out of 1,000 women with the same profile, one would have a baby with the condition. A result of 1 in 10,000 is considered very low risk. A result of 1 in 150 or lower is usually classified as "high risk" and triggers an offer of further testing.
NIPT: the newer, more accurate blood test
In the last decade, a different kind of blood test has become available: Non-Invasive Prenatal Testing (NIPT), also called cell-free DNA (cfDNA) testing. It is not the same as the combined test. It is newer, more accurate, and works differently.
During pregnancy, small fragments of the baby's DNA circulate in the mother's blood. NIPT analyses these fragments. It can detect the common trisomies (21, 18, and 13) with high accuracy — a positive predictive value of roughly 90% or more for Down syndrome, depending on the mother's age. It can also determine the baby's sex and, in some expanded panels, screen for sex chromosome differences and microdeletion syndromes.
Important limitations of NIPT:
- It is still a screening test, not diagnostic. A "high risk" NIPT result needs confirmation through CVS or amniocentesis.
- It is less accurate in women with higher body weight, in twin pregnancies (unless using specialised twin panels), and in pregnancies conceived through egg donation or surrogacy.
- False positives and false negatives both happen, though they are rare.
- It does not screen for physical structural problems — only chromosomal ones. The NT scan and the 20-week anomaly scan still matter.
In many countries, NIPT is offered to all pregnant women, sometimes at a cost, sometimes covered by insurance or the national health system. In other countries it is only offered after a high-risk combined screening result.
When the screening comes back high risk
A high-risk screening result — whether from the combined test or NIPT — is not a diagnosis. It means the chance is high enough that a diagnostic test is recommended to give a definitive answer. The two diagnostic tests are CVS and amniocentesis.
Chorionic Villus Sampling (CVS)
CVS is usually performed between 11 and 14 weeks. A thin needle is inserted through the abdomen or the cervix to take a small sample of tissue from the placenta. Because the placenta comes from the same fertilised egg as the baby, its chromosomes usually match the baby's exactly. The sample is grown in a laboratory and analysed under a microscope (karyotyping) or with molecular techniques (FISH, microarray, or rapid PCR).
CVS carries a small risk of miscarriage — approximately 1 in 500 to 1 in 1,000, depending on the operator's experience and the method used. It can diagnose chromosomal conditions, single-gene disorders (if specifically tested), and some microdeletions. It cannot detect neural tube defects, which develop later.
Amniocentesis
Amniocentesis is usually performed after 15 weeks. A needle is inserted through the abdomen into the amniotic sac, and a small amount of amniotic fluid is withdrawn. The fluid contains cells shed by the baby, which are then cultured and analysed.
Amniocentesis carries a similar miscarriage risk to CVS — roughly 1 in 500 to 1 in 1,000. It can diagnose all chromosomal conditions that CVS can, and it can also detect neural tube defects because the fluid contains proteins associated with spine and brain development. It is preferred after 15 weeks because it is technically safer later in pregnancy.
Understanding the numbers
Screening and diagnostic testing are often misunderstood because the numbers are unintuitive. Here is what the research shows, based on large population studies:
- The combined first-trimester screening test detects roughly 85–90% of babies with Down syndrome, with a false positive rate of about 5%. That means 5% of women with a completely normal pregnancy will be told they are high risk and offered an invasive test.
- NIPT detects over 99% of Down syndrome cases, with a false positive rate below 0.1%. For Edwards and Patau syndromes, detection rates are slightly lower but still very high.
- The positive predictive value of NIPT depends heavily on the mother's age. In a 25-year-old, a positive NIPT for Down syndrome is still more likely to be false than true. In a 40-year-old, a positive NIPT is almost certainly correct.
- CVS and amniocentesis are the only tests that give a definitive yes or no answer. They are the diagnostic gold standard.
What the NT scan cannot do
It is important to understand the limits of first-trimester screening:
- A normal NT measurement and a low-risk combined test do not guarantee a healthy baby. They only mean the risk of the screened conditions is low. Structural problems, genetic conditions not on the panel, and many other issues cannot be ruled out at this stage.
- An abnormal NT does not mean the baby has a chromosomal condition. Many babies with increased NT turn out to be completely healthy. The NT is a soft marker, not a diagnosis.
- The scan cannot tell you how severe a condition would be if it is present. Two children with the same chromosomal diagnosis can have very different outcomes.
Preparing for the scan
The NT scan requires a full bladder in many clinics, so drink water beforehand. The timing window is strict — the baby must measure between 45 and 84 millimetres crown-to-rump length, which corresponds to roughly 11 weeks to 13 weeks 6 days. If you arrive too early or too late, the scan may need to be rescheduled.
Bring your partner or a support person if you can. The scan is usually longer than a dating scan because the sonographer must wait for the baby to move into the exact position needed for the measurement. Sometimes this takes patience. Sometimes you are asked to walk, cough, or return later.
Making decisions after the results
If your screening comes back high risk, you will usually be offered an appointment with a genetic counsellor or fetal medicine specialist. This is not an emergency. You have time. The counsellor's job is not to tell you what to do. It is to help you understand the numbers, the tests, and the implications, so you can make a decision that is right for your family.
Some parents want every test available. Others decline further testing. Both choices are valid. What matters is that the choice is informed, supported, and free from pressure.
Sources and further reading
- National Health Service (NHS). "Screening for Down's syndrome, Edwards' syndrome and Patau's syndrome." www.nhs.uk
- Royal College of Obstetricians and Gynaecologists (RCOG). "Chorionic Villus Sampling (CVS) and Amniocentesis: Information for You." www.rcog.org.uk
- American College of Obstetricians and Gynecologists (ACOG). "Screening for Fetal Chromosomal Abnormalities." Practice Bulletin No. 226. www.acog.org
- Nicolaides KH. "Nuchal translucency and other first-trimester sonographic markers of chromosomal abnormalities." American Journal of Obstetrics and Gynecology, 2004. PubMed
- Benn P, Borrell A, Chiu R, et al. "Position statement from the Chromosome Abnormality Screening Committee on behalf of the Board of the International Society for Prenatal Diagnosis." Prenatal Diagnosis, 2015. PubMed
- Gil MM, Accurti V, Santacruz B, et al. "Analysis of cell-free DNA in maternal blood in screening for aneuploidies: updated meta-analysis." Ultrasound in Obstetrics & Gynecology, 2017. PubMed
This information is for educational purposes and does not replace medical advice. Always discuss screening and testing decisions with your healthcare provider.
